Annovis up 23% after webinar on neurodegeneration candidates
Thinly traded nano cap Annovis Bio (ANVS +22.6%) bucks the broad market's bearishness, albeit on turnover of only 54K shares. After the close yesterday, CEO Maria Maccecchini, Ph.D., hosted an online Q&A session about recent developments at the company.
Thinly traded nano cap Annovis Bio (ANVS +22.6%) bucks the broad market's bearishness, albeit on turnover of only 54K shares. After the close yesterday, CEO Maria Maccecchini, Ph.D., hosted an online Q&A session about recent developments at the company.